Safety and immunogenicity of a high-potency inactivated hepatitis A vaccine

Journal of Travel Medicine

Volumn 3, Issue 2, 1996, Pages 83-90

  Van Damme, Pierre ^a   Thoelen, Stefan ^a   Cramm, Myrjam ^a   Meheus, André ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002035028     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1996.tb00711.x     Document Type: Article

References (38)

1. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger BF, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:14-20.
2. Tilzey AJ, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. BMJ 1991;302:1552-1553.
3. Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis 1986;8:548-557.
4. Tabor E. Clinical presentation of hepatitis A. In: Gerety RJ, ed. Hepatitis A. Orlando: Academic Press, 1984:47-53.
5. Centers for Disease Control and Prevention. Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40:48-50.
6. André FE, Hepburn A, D'Hondt E. Inactivated candidate vaccines for hepatitis A. In: Melnick JC, ed. Progress in medical virology. Vol. 37. Basel: Karger, 1990:72-95.
7. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-457.
8. Loutan L, Bovier P, Althans B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994;343:322-324.
9. Anonymous. Hepatitis A: a vaccine at last. Lancet 1992; 339:1198-1199.
10. André FE, d'Hondt ED, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992; 10(Suppl):160-168.
11. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1134-1138.
12. Purcell RH, D'Hondt E, Bradbury R, et al. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 1992;10(Suppl):148-151.
13. Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994;272:885-889.
14. Van Damme P, Gramm M, Van Compel A, et al. Analysis of travellers profile in Belgium. Paris: Proceedings of the Third Conference on International Travel Medicine, April 26-29, 1993: Abstract No. 267.
15. Van Damme P, Thoelen S, Van der Auwera JC, et al. Health care workers and hepatitis A. In: Hagberg M, Hoffman F, Stössel U, Westlander G, eds. Occupational health for health care workers. Freiburg, Stuttgart: Ecomed-Verlag, 1993:133-137.
16. Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis among health care workers: risk factors for transmission. Am J Public Health 1993;83:1679-1684.
17. Delem A. Comparison of modified HAVAB and Elisa for detection of vaccine-induced anti-HAV response. Biologicals 1992;20:289-291.
18. Ambrosch F, Wiedermann G, André F, et al. Comparison of HAV antibodies induced by vaccination, passive immunization, and natural infection. In: Holinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:98-100.
19. Binn LN, MacArthy PO, Marchwicki RH, et al. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine. Vaccine 1992;10(Suppl):102-105.
20. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983;148:1033-1039.
21. Tilzey AJ, Palmer SJ, Barro S, et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992;304:1272-1276.
22. Kallinowski B, Gmelin K, Kommerell B, et al. Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine - a randomized multicentre study with three consecutive vaccine lots. Vaccine 1992;10:500-501.
23. Van Damme P, Mathei C, Thoelen S, et al. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44: 435-441.
24. Davidson M, Krugman S, Sandman LA. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. Vaccine 1992;10(Suppl):119-120.
25. Tilzey AJ, Palmer SJ, Barrow S, et al. Effect of hepatitis A vaccination schedules on immune response. Vaccine 1992; 10(Suppl):121-123.
26. Wiedermann G, Ambrosch F, André FE, et al. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992; 10(Suppl):129-131.
27. Thoelen S, Van Damme P, Cramm M, et al. The safety, reactogenicity and longterm immunogenicity of two lots of an inactivated hepatitis A vaccine. In: Hagberg M, Hoffman F, Stössel U, Westlander G, eds. Occupational health for health care workers. Freiburg, Stuttgart: Ecomed-Verlag, 1993: 156-160.
28. Westblom TU, Gudipati S, De Rousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994; 169: 996-1001.
29. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross-protection. N Engl J Med 1982;307:1481-1489.
30. Hollinger BF. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989;87(3A):36-40.
31. Hollinger BF, Troisi C, Heilberg D, et al. Response to a hepatitis B polypeptide vaccine in micelle form in a young adult population. J Med Virol 1986;19:229-235.
32. Denis F, Mounier M, Hessel L, et al. Hepatitis-B vaccination in the elderly. J Infect Dis 1984;149:1019.
33. Ljunggren K, Löfgren B, Nordenfelt E. Varying antibody response in hospital staff vaccinated against hepatitis B. Scand J Infect Dis 1988;20:485-488.
34. Briem H, Wynen J, Safary A. Immunogenicity and reactogenicity of a hepatitis A virus (HAV) vaccine administered as a single dose with a booster at 6 months. Tokyo: International Symposium on Viral Hepatitis and Liver Disease, May 10-14, 1993:110(Abstract No. 48).
35. Just M, Gremmelmaier D, Berger R, et al. Safety and immunogenicity of dose of inactivated hepatitis A vaccine in healthy adults. Tokyo: International Symposium on Viral Hepatitis and Liver Disease, May 10-14, 1993:105 (Abstract No. 29).
36. André FE. Development of a vaccine against hepatitis A. In: Hollinger BF, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:85-88.
37. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and longterm antibody persistence. J Med Virol 1994;44:446-451.
38. Beller M, Krause D. Experience with Havrix in an outbreak setting. Prague: Sixth International Congress for Infectious Diseases, 1994:282 (Abstract No. 878).